Clinical trial designs for multiple myeloma.

  title={Clinical trial designs for multiple myeloma.},
  author={Antje Hoering and John J. Crowley},
  journal={Clinical advances in hematology & oncology : H&O},
  volume={5 4},
The development of new anti-myeloma agents with different mechanisms of action from conventional chemotherapy has necessitated a new look at clinical trial design. We discuss design issues for cytostatic agents for phase I, II, and III clinical trials pertaining to myeloma. The success of phase I trials with cytotoxic agents is predicated on the dose toxicity curve being strictly monotone. With cytostatic agents, however, the shape of the dose toxicity curve is not necessarily monotone, and… CONTINUE READING